Brusatol-mediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-myc

Leukemia

Volumn 16, Issue 11, 2002, Pages 2275-2284

  Mata Greenwood, E ^a   Cuendet, M ^a   Sher, D ^a   Gustin, D ^a   Stock, W ^a   Pezzuto, J M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Brusatol; c MYC; Cell differentiation; Cytotoxicity; Quassinoids

Indexed keywords

BRUCEANTIN; BRUSATOL; CD15 ANTIGEN; ESTERASE; MICROSOMAL AMINOPEPTIDASE; MYC PROTEIN; QUASSINOID DERIVATIVE; RNA; SUPEROXIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL MATURATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ERYTHROCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; UPREGULATION;

EID: 0036849687     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402696     Document Type: Article

References (53)

1. Sachs L. Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia: a model for the origin and progression of malignancy. Proc Natl Acad Sci USA 1980; 77: 6152-6156.
2. Huang M-E, Ye Y-C, Chen S-R, Chai J-R, Lu J-X, Lin Z, Gu L-J, Wang Z-Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
3. Warrell RP, de Thé H, Wang Z-Y, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-189.
4. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 1994; 76: 345-356.
5. Daniel MT, Koken M, Romagné O, Barbey S, Bazarbachi A, Stadler M, Guilemin MC, Degos L, Chomienne C, de Thé H. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82: 1858-1867.
6. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76: 333-343.
7. Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CCP 57148. Cell Death Differ 1998; 5: 710-715.
8. Dalla Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Assignment of the human c-myc oncogene to the region of chromosome 8 which is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7827.
9. Ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the translocated and of the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983; 222: 390-393.
10. Ryan KM, Birnie GD. Myc oncogenes: the enigmatic family. Biochem J 1996; 314: 713-721.
11. Collins JF, Herman P, Schuch C, Bagby GC Jr. c-Myc antisense oligonucleotides inhibit the colony-forming capacity of Colo320 colonic carcinoma cells. J Clin Invest 1992; 9: 1523-1527.
12. Negroni A, Scarpa S, Romeo A, Ferrari S, Modesti A, Raschella G. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 1991; 2: 511-518.
13. Nguyen HQ, Selvakumaran M, Liebermann DA, Hoffman B. Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells. Oncogene 1995; 11: 2439-2444.
14. Stöcker U, Schaefer A, Marquardt H. DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracycline antitumor antibiotic aclarubicin. Leukemia 1995; 9: 146-154.
15. Kharbanda SM, Sherman ML, Spriggs DR, Kufe DW. Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation. Cancer Res 1988; 48: 5965-5968.
16. Baker SJ, Pawlita M, Leutz A, Hoelzer D. Essential role of c-myc in ara-C induced differentiation of human erythroleukemia cells. Leukemia 1994; 8: 1309-1317.
17. Linevsky J, Cohen MB, Hartman KD, Knode MC, Glazer RI. Effect of neplanocin A on differentiation, nucleic acid methylation, and c-myc mRNA expression in human promyelocytic leukemia cells. Mol Pharmacol 1985; 28: 45-50.
18. Rabbits A, Watson JV, Lamond A, Forster A, Stinson A, Evan G, Fischer W, Atherton E, Sheppard E, Rabbitts TH. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J 1985; 4: 2009-2015.
19. Spotts CD, Hann SR. Enhanced translation and increased turnover of c-myc proteins occur during differentiation of murine erythroleukemia cells. Mol Cell Biol 1990; 8: 3952-3964.
20. Tang W, Eisenbrand G. Brucea javanica (L.) Merr. In: W Tang, Eisenbrand G (eds). Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine. Springer-Verlag: Berlin, 1992, pp 207-222.
21. Liao LL, Kupchan SM, Horwitz SB. Mode of action of the anti-tumor compound bruceantin, an inhibitor of protein synthesis. Mol Pharmacol 1976; 12: 167-176.
22. Fresno M, Gonzales A, Vazquez D, Jimenez A. Bruceantin, a novel inhibitor of peptide bond formation. Biochim Biophys Acta 1978; 518: 104-112.
23. Hall IH, Lee KH, Eigebaly SA, Imakura Y, Sumida Y, Wu RY. Anti-tumor agents XXXIV: mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells. J Pharm Sci 1979; 68: 883-887.
24. Liesmann J, Belt RJ, Haas CD, Hoogstraten B. Phase I study on bruceantin administered on a weekly schedule. Cancer Treat Rep 1981; 65: 883-885.
25. Bedikian AY, Valdivieso M, Bodey CP, Murphy WK, Freireich EJ. Initial clinical studies with bruceantin. Cancer Treat Rep 1979; 63:1843-1847.
26. Wiseman CL, Yap HY, Bedikian AY, Bodey GP, Blumenschein GR. Phase II trial of bruceantin in metastatic breast carcinoma. Am J Clin Oncol 1982; 5: 389-391.
27. Arsenau JC, Wolter JM, Kuperminc M, Ruckdeschel, JC. A Phase II study of bruceantin (NSC 165563) in advanced malignant melanoma. Invest New Drugs 1983; 1: 239-242.
28. Sub N, Luyengi L, Fong HHS, Kinghorn AD, Pezzuto JM. Discovery of natural product chemopreventive agents utilizing HL-60 cell differentiation as a model. Anticancer Res 1995; 15: 233-240.
29. Luyengi L, Suh N, Fong HHS, Pezzuto JM, Kinghorn AD. A Iignan and four terpenoids from Brucea javanica that induce differentiation with cultured HL-60 promyelocytic leukemia cells. Phytochemistry 1996; 43: 409-412.
30. 3 or 12-O-tetradecanoyl phorbol 13-acetate. Leuk Res 1998; 22: 537-547.
31. VindelØ LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323-327.
32. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-5708.
33. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987; 70: 1233-1244.
34. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321-334.
35. Asou H, Tashiro, S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
36. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1992; 77: 1080-1085.
37. Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565-577.
38. Pegoraro L, Matera L, Ritz J, Levis A, Palumbo A, Biagini G. Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst 1983; 70: 447-453.
39. Naumovski L, Morgan R, Hecht F, Link MP, Glader BE, Smith SD. Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines without classical breakpoint cluster region rearrangement. Cancer Res 1988; 48: 2876-2879.
40. Abe R, Sandberg A. Significance of abnormalities involving chromosomal segment 11q23-25 in acute leukemia. Cancer Genet Cytogenet 1984; 13: 121-126.
41. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan G-F, Pui C-H, Grosveld G, Downing JR. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989.
42. Epstein AL, Levy R, Kim H, Henle W, Henle G, Kaplan HS. Biology of the human malignant lymphomas. Cancer 1978; 42: 2379-2391.
43. Bocchia M, Xu Q, Wesley U, Xu Y, Korontsvit T, Loganzo F, Albino AP, Scheinberg DA. Modulation of p53, WAF1/p2l and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Leuk Res 1997; 21: 439-447.
44. Lbbert M, Miller CW, Crawford L, Koeffler HP. p53 in chronic myelogenous leukemia. J Exp Med 1988; 167: 873-886.
45. Hendrikse AS, Hunter AJ, Keraan M, Blekkenhorst CH. Effects of low dose irradiation on TK6 and U937 cells: induction of p53 and its role in cell-cycle delay and the adaptive response. Int J Radiat Biol 2000; 76: 11-21.
46. Furuwatari C, Yagi A, Yamagami O, Ishikawa M, Hidaka E, Ueno I, Furihata K, Ogiso Y, Katsuyama, T. A comprehensive system to explore p53 mutations. Am J Clin Pathol 1998; 110: 368-373.
47. Aldridge DR, Radford IR. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res 1998; 58: 2817-2824.
48. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20: 5595-5610.
49. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1991; 254: 1161-1167.
50. de Alboran IM, O'Hagan RC, Gaertner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW. Analysis of c-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001; 14: 45-55.
51. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Matin GR, Bishop JM. C-Myc regulated mammalian body size by controlling cell number but not cell size. Nature 2001 ; 414: 768-773.
52. 2 phase of the cells cycle. Mol Cell Biol 2001; 21: 4929-4937.
53. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995; 57: 131-141.